{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T11:15:41Z","timestamp":1788520541759,"version":"build-2803163510"},"reference-count":162,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T00:00:00Z","timestamp":1751846400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T00:00:00Z","timestamp":1751846400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Cell Int"],"DOI":"10.1186\/s12935-025-03869-w","type":"journal-article","created":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T16:52:33Z","timestamp":1751907153000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["One step further in targeting acute leukemia by combining antibody-based immunotherapies and small molecule inhibitors"],"prefix":"10.1186","volume":"25","author":[{"given":"Armin","family":"Dozandeh-Jouybari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erfan","family":"Rohaninia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Faaliat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nazanin","family":"Joudaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Ghandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam Talebi","family":"Moghaddam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8813-6046","authenticated-orcid":false,"given":"Saeid","family":"Taghiloo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8583-1270","authenticated-orcid":false,"given":"Tohid","family":"Kazemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,7]]},"reference":[{"key":"3869_CR1","doi-asserted-by":"publisher","first-page":"e28371","DOI":"10.1002\/pbc.28371","volume":"68","author":"JHC Chang","year":"2021","unstructured":"Chang JHC, Poppe MM, Hua CH, Marcus KJ, Esiashvili N. Acute lymphoblastic leukemia. Pediatr Blood Cancer. 2021;68:e28371.","journal-title":"Pediatr Blood Cancer"},{"issue":"3","key":"3869_CR2","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1002\/ajh.26822","volume":"98","author":"S Shimony","year":"2023","unstructured":"Shimony S, Stahl M, Stone RM. Acute myeloid leukemia: 2023 update on diagnosis, risk-stratification, and management. Am J Hematol. 2023;98(3):502\u201326.","journal-title":"Am J Hematol"},{"issue":"11","key":"3869_CR3","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.1080\/03007995.2019.1631149","volume":"35","author":"NL Crossnohere","year":"2019","unstructured":"Crossnohere NL, Richardson DR, Reinhart C, O\u2019Donoghue B, Love SM, Smith BD, Bridges JF. Side effects from acute myeloid leukemia treatment: results from a national survey. Curr Med Res Opin. 2019;35(11):1965\u201370.","journal-title":"Curr Med Res Opin"},{"key":"3869_CR4","volume-title":"Acute leukemia-the scientist's perspective and challenge","author":"JM Vagace","year":"2011","unstructured":"Vagace JM, Gervasini G. Chemotherapy toxicity in patients with acute leukemia. In: Antica M, editor. Acute leukemia-the scientist\u2019s perspective and challenge. London: Intechopen; 2011."},{"issue":"7","key":"3869_CR5","doi-asserted-by":"publisher","first-page":"717","DOI":"10.3109\/07357907.2010.494319","volume":"28","author":"H Asgarian-Omran","year":"2010","unstructured":"Asgarian-Omran H, Forghani P, Hojjat-Farsangi M, Roohi A, Sharifian RA, Razavi SM, et al. Expression profile of galectin-1 and galectin-3 molecules in different subtypes of chronic lymphocytic leukemia. Cancer Invest. 2010;28(7):717\u201325.","journal-title":"Cancer Invest"},{"issue":"10","key":"3869_CR6","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1016\/j.trecan.2019.07.009","volume":"5","author":"MT Witkowski","year":"2019","unstructured":"Witkowski MT, Lasry A, Carroll WL, Aifantis I. Immune-based therapies in acute leukemia. Trends in cancer. 2019;5(10):604\u201318.","journal-title":"Trends in cancer"},{"issue":"16","key":"3869_CR7","doi-asserted-by":"publisher","first-page":"4137","DOI":"10.3390\/cancers15164137","volume":"15","author":"A Chergui","year":"2023","unstructured":"Chergui A, Reagan JL. Immunotherapy in acute leukemias: past success paves the way for future progress. Cancers. 2023;15(16):4137.","journal-title":"Cancers"},{"issue":"2","key":"3869_CR8","doi-asserted-by":"publisher","first-page":"315","DOI":"10.4143\/crt.2022.078","volume":"54","author":"J Rivera-Concepcion","year":"2022","unstructured":"Rivera-Concepcion J, Uprety D, Adjei AA. Challenges in the use of targeted therapies in non-small cell lung cancer. Cancer Res Treat. 2022;54(2):315\u201329.","journal-title":"Cancer Res Treat"},{"key":"3869_CR9","doi-asserted-by":"publisher","first-page":"737340","DOI":"10.3389\/fimmu.2021.737340","volume":"12","author":"S Jim\u00e9nez-Morales","year":"2021","unstructured":"Jim\u00e9nez-Morales S, Aranda-Uribe IS, P\u00e9rez-Amado CJ, Ram\u00edrez-Bello J, Hidalgo-Miranda A. Mechanisms of immunosuppressive tumor evasion: focus on acute lymphoblastic leukemia. Front Immunol. 2021;12:737340.","journal-title":"Front Immunol"},{"key":"3869_CR10","doi-asserted-by":"publisher","first-page":"103164","DOI":"10.1016\/j.critrevonc.2020.103164","volume":"157","author":"S Taghiloo","year":"2021","unstructured":"Taghiloo S, Asgarian-Omran H. Immune evasion mechanisms in acute myeloid leukemia: a focus on immune checkpoint pathways. Crit Rev Oncol Hematol. 2021;157:103164.","journal-title":"Crit Rev Oncol Hematol"},{"key":"3869_CR11","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.19519","author":"WY Jen","year":"2024","unstructured":"Jen WY, Kantarjian H, Kadia TM, DiNardo CD, Issa GC, Short NJ, et al. Combination therapy with novel agents for acute myeloid leukaemia: Insights into treatment of a heterogenous disease. British J Haematol. 2024. https:\/\/doi.org\/10.1111\/bjh.19519.","journal-title":"British J Haematol"},{"issue":"3","key":"3869_CR12","first-page":"153","volume":"80","author":"P Dami\u00e1n-Blanco","year":"2023","unstructured":"Dami\u00e1n-Blanco P, Ahuexoteco-S\u00e1nchez S, Carbajal-Gallardo AA, Coctecon-Ch\u00e1velas FC, Rodr\u00edguez-Nava C, Vences-Vel\u00e1zquez A, et al. Use of monoclonal antibodies in cancer immunotherapy: types and mechanisms of action. Bol Med Hosp Infant Mex. 2023;80(3):153\u201364.","journal-title":"Bol Med Hosp Infant Mex"},{"key":"3869_CR13","doi-asserted-by":"publisher","first-page":"385","DOI":"10.3109\/10428199509059636","volume":"18","author":"R Scheuermann","year":"1995","unstructured":"Scheuermann R, Racila E. CD19 antigen in leukemia and lymphoma diagnosis and immunotherapy. Leukemia Lymphoma. 1995;18:385\u201397.","journal-title":"Leukemia Lymphoma"},{"issue":"4","key":"3869_CR14","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1080\/14712598.2021.1884677","volume":"21","author":"G Salles","year":"2021","unstructured":"Salles G, D\u0142ugosz-Danecka M, Ghesqui\u00e8res H, Jurczak W. Tafasitamab for the treatment of relapsed or refractory diffuse large B-cell lymphoma. Expert Opin Biol Ther. 2021;21(4):455\u201363.","journal-title":"Expert Opin Biol Ther"},{"key":"3869_CR15","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1182\/bloodadvances.2019000767","volume":"4","author":"N Jain","year":"2020","unstructured":"Jain N, Stock W, Zeidan A, Atallah E, McCloskey J, Heffner L, et al. Loncastuximab tesirine, an anti-CD19 antibody-drug conjugate, in relapsed\/refractory B-cell acute lymphoblastic leukemia. Blood Adv. 2020;4:449\u201357.","journal-title":"Blood Adv"},{"issue":"24","key":"3869_CR16","doi-asserted-by":"publisher","first-page":"3880","DOI":"10.1200\/JCO.2009.26.9456","volume":"28","author":"DA Thomas","year":"2010","unstructured":"Thomas DA, O\u2019Brien S, Faderl S, Garcia-Manero G, Ferrajoli A, Wierda W, et al. Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome\u2013negative precursor B-lineage acute lymphoblastic leukemia. J Clin Oncol. 2010;28(24):3880\u20139.","journal-title":"J Clin Oncol"},{"issue":"11","key":"3869_CR17","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1056\/NEJMoa1605085","volume":"375","author":"S Maury","year":"2016","unstructured":"Maury S, Chevret S, Thomas X, Heim D, Leguay T, Huguet F, et al. Rituximab in B-lineage adult acute lymphoblastic leukemia. N Engl J Med. 2016;375(11):1044\u201353.","journal-title":"N Engl J Med"},{"issue":"7","key":"3869_CR18","doi-asserted-by":"publisher","first-page":"e523","DOI":"10.1016\/S2352-3026(20)30144-7","volume":"7","author":"E Jabbour","year":"2020","unstructured":"Jabbour E, Richard-Carpentier G, Sasaki Y, Konopleva M, Patel K, Roberts K, et al. Hyper-CVAD regimen in combination with ofatumumab as frontline therapy for adults with Philadelphia chromosome-negative B-cell acute lymphoblastic leukaemia: a single-arm, phase 2 trial. Lancet Haematol. 2020;7(7):e523\u201333.","journal-title":"Lancet Haematol"},{"issue":"7","key":"3869_CR19","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1002\/pbc.25454","volume":"62","author":"EA Raetz","year":"2015","unstructured":"Raetz EA, Cairo MS, Borowitz MJ, Lu X, Devidas M, Reid JM, et al. Re-induction chemoimmunotherapy with epratuzumab in relapsed acute lymphoblastic leukemia (ALL): phase II results from Children\u2019s Oncology Group (COG) study ADVL04P2. Pediatr Blood Cancer. 2015;62(7):1171\u20135.","journal-title":"Pediatr Blood Cancer"},{"issue":"8","key":"3869_CR20","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1056\/NEJMoa1509277","volume":"375","author":"HM Kantarjian","year":"2016","unstructured":"Kantarjian HM, DeAngelo DJ, Stelljes M, Martinelli G, Liedtke M, Stock W, et al. Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia. N Engl J Med. 2016;375(8):740\u201353.","journal-title":"N Engl J Med"},{"issue":"4","key":"3869_CR21","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1038\/s41375-018-0265-z","volume":"33","author":"D Bhojwani","year":"2019","unstructured":"Bhojwani D, Sposto R, Shah NN, Rodriguez V, Yuan C, Stetler-Stevenson M, et al. Inotuzumab ozogamicin in pediatric patients with relapsed\/refractory acute lymphoblastic leukemia. Leukemia. 2019;33(4):884\u201392.","journal-title":"Leukemia"},{"issue":"9","key":"3869_CR22","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1038\/leu.2017.187","volume":"31","author":"C Godwin","year":"2017","unstructured":"Godwin C, Gale R, Walter RJL. Gemtuzumab ozogamicin in acute myeloid leukemia. Leukemia. 2017;31(9):1855\u201368.","journal-title":"Leukemia"},{"issue":"10","key":"3869_CR23","doi-asserted-by":"publisher","first-page":"2030","DOI":"10.1158\/1078-0432.CCR-21-3712","volume":"28","author":"TL Rosenblat","year":"2022","unstructured":"Rosenblat TL, McDevitt MR, Carrasquillo JA, Pandit-Taskar N, Frattini MG, Maslak PG, et al. Treatment of patients with acute myeloid leukemia with the targeted alpha-particle nanogenerator actinium-225-lintuzumab. Clin Cancer Res. 2022;28(10):2030\u20137.","journal-title":"Clin Cancer Res"},{"key":"3869_CR24","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-23-0720","author":"T Satomaa","year":"2024","unstructured":"Satomaa T, Pynn\u00f6nen H, Aitio O, Hiltunen JO, Pitk\u00e4nen V, L\u00e4hteenm\u00e4ki T, et al. Targeting CD33+ acute myeloid leukemia with GLK-33, a Lintuzumab-Auristatin conjugate with a wide therapeutic window. Mol Cancer Ther. 2024. https:\/\/doi.org\/10.1158\/1535-7163.MCT-23-0720.","journal-title":"Mol Cancer Ther"},{"issue":"12","key":"3869_CR25","doi-asserted-by":"publisher","first-page":"2977","DOI":"10.3324\/haematol.2022.281128","volume":"107","author":"W Fiedler","year":"2022","unstructured":"Fiedler W, Montesinos P, Schliemann C, Middeke J, Vasu S, Scholz CW, et al. An open-label, phase I\/II trial to determine the maximum tolerated dose and investigate safety, pharmacokinetics and efficacy of BI 836858, an unconjugated anti-CD33 monoclonal antibody, in combination with decitabine in patients with acute myeloid leukemia. Haematologica. 2022;107(12):2977.","journal-title":"Haematologica"},{"key":"3869_CR26","doi-asserted-by":"publisher","first-page":"1007783","DOI":"10.3389\/fonc.2022.1007783","volume":"12","author":"X Zhong","year":"2022","unstructured":"Zhong X, Ma H. Targeting CD38 for acute leukemia. Front Oncol. 2022;12:1007783.","journal-title":"Front Oncol"},{"key":"3869_CR27","doi-asserted-by":"crossref","unstructured":"Hogan LE, Bhatla T, Teachey DT, Sirvent FJB, Moppett J, Puy\u00f3 PV, et al. Efficacy and safety of daratumumab (DARA) in pediatric and young adult patients (pts) with relapsed\/refractory T-cell acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LL): results from the phase 2 DELPHINUS study. Am Soc Clin Oncol. 2022. https:\/\/doi.org\/10.1200\/JCO.2022.40.16_suppl.10001.","DOI":"10.1200\/JCO.2022.40.16_suppl.10001"},{"issue":"5","key":"3869_CR28","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1002\/cam4.4478","volume":"11","author":"N Boissel","year":"2022","unstructured":"Boissel N, Chevallier P, Doronin V, Griskevicius L, Maschan A, McCloskey J, et al. Isatuximab monotherapy in patients with refractory T-acute lymphoblastic leukemia or T-lymphoblastic lymphoma: Phase 2 study. Cancer Med. 2022;11(5):1292\u20138.","journal-title":"Cancer Med"},{"key":"3869_CR29","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1182\/blood-2021-150272","volume":"138","author":"A Baruchel","year":"2021","unstructured":"Baruchel A, Abrahamsson J, Bertrand Y, Gonzalez O, Nysom K, Quinones W, et al. Isatuximab in combination with chemotherapy in pediatric patients with relapsed\/refractory acute lymphoblastic leukemia or acute myeloid leukemia (ISAKIDS): interim analysis. Blood. 2021;138:516.","journal-title":"Blood"},{"issue":"12","key":"3869_CR30","first-page":"2645","volume":"106","author":"R Tibes","year":"2006","unstructured":"Tibes R, Keating MJ, Ferrajoli A, Wierda W, Ravandi F, Garcia-Manero G, et al. Activity of alemtuzumab in patients with CD52-positive acute leukemia. Cancer Interdiscipl Int J Am Cancer Soc. 2006;106(12):2645\u201351.","journal-title":"Cancer Interdiscipl Int J Am Cancer Soc"},{"issue":"1","key":"3869_CR31","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1158\/1078-0432.CCR-16-1022","volume":"23","author":"K Sharma","year":"2017","unstructured":"Sharma K, Janik JE, O\u2019Mahony D, Stewart D, Pittaluga S, Stetler-Stevenson M, et al. Phase II study of Alemtuzumab (CAMPATH-1) in patients with HTLV-1\u2013associated adult T-cell leukemia\/lymphoma. Clin Cancer Res. 2017;23(1):35\u201342.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"3869_CR32","doi-asserted-by":"publisher","first-page":"2718","DOI":"10.3390\/ijms24032718","volume":"24","author":"E Pelosi","year":"2023","unstructured":"Pelosi E, Castelli G, Testa U. CD123 a therapeutic target for acute myeloid leukemia and blastic plasmocytoid dendritic neoplasm. Int J Mol Sci. 2023;24(3):2718.","journal-title":"Int J Mol Sci"},{"issue":"3","key":"3869_CR33","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/S1470-2045(23)00674-5","volume":"25","author":"NG Daver","year":"2024","unstructured":"Daver NG, Montesinos P, DeAngelo DJ, Wang ES, Papadantonakis N, Todisco E, et al. Pivekimab sunirine (IMGN632), a novel CD123-targeting antibody\u2013drug conjugate, in relapsed or refractory acute myeloid leukaemia: a phase 1\/2 study. Lancet Oncol. 2024;25(3):388\u201399.","journal-title":"Lancet Oncol"},{"issue":"1","key":"3869_CR34","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1038\/s41375-020-0773-5","volume":"35","author":"P Montesinos","year":"2021","unstructured":"Montesinos P, Roboz GJ, Bulabois C-E, Subklewe M, Platzbecker U, Ofran Y, et al. Safety and efficacy of talacotuzumab plus decitabine or decitabine alone in patients with acute myeloid leukemia not eligible for chemotherapy: results from a multicenter, randomized, phase 2\/3 study. Leukemia. 2021;35(1):62\u201374.","journal-title":"Leukemia"},{"issue":"12","key":"3869_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s12276-018-0191-1","volume":"50","author":"P Darvin","year":"2018","unstructured":"Darvin P, Toor SM, Sasidharan Nair V, Elkord E. Immune checkpoint inhibitors: recent progress and potential biomarkers. Exp Mol Med. 2018;50(12):1\u201311.","journal-title":"Exp Mol Med"},{"issue":"4","key":"3869_CR36","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1158\/2159-8290.CD-20-1680","volume":"11","author":"P Sharma","year":"2021","unstructured":"Sharma P, Siddiqui BA, Anandhan S, Yadav SS, Subudhi SK, Gao J, et al. The next decade of immune checkpoint therapy. Cancer Discov. 2021;11(4):838\u201357.","journal-title":"Cancer Discov"},{"issue":"15","key":"3869_CR37","doi-asserted-by":"publisher","first-page":"1884","DOI":"10.1182\/blood.2022017686","volume":"141","author":"JS Garcia","year":"2023","unstructured":"Garcia JS, Flamand Y, Penter L, Keng M, Tomlinson BK, Mendez LM, et al. Ipilimumab plus decitabine for patients with MDS or AML in posttransplant or transplant-na\u00efve settings. Blood. 2023;141(15):1884\u20138.","journal-title":"Blood"},{"key":"3869_CR38","doi-asserted-by":"publisher","DOI":"10.7754\/Clin.Lab.2021.210701","author":"SO Hamdan","year":"2022","unstructured":"Hamdan SO, Sughayer M, Khader M, Tbakhi A, Khudirat S, Hejazi A, et al. Programmed death ligand-1 is frequently expressed in primary acute myeloid leukemia and B-acute lymphoblastic leukemia. Clin Lab. 2022. https:\/\/doi.org\/10.7754\/Clin.Lab.2021.210701.","journal-title":"Clin Lab"},{"key":"3869_CR39","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1182\/blood-2021-154467","volume":"138","author":"S Suo","year":"2021","unstructured":"Suo S, Li F, Zhao D, Qiao J, Liang C, Hoang DH, et al. Acute myeloid leukemia cell-intrinsic PD-1 functions promoting leukemia development By recruiting SHP2. Blood. 2021;138:1173.","journal-title":"Blood"},{"issue":"1","key":"3869_CR40","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1186\/s40001-023-01352-8","volume":"28","author":"Y Ruan","year":"2023","unstructured":"Ruan Y, Wang J, Zhang Q, Wang H, Li C, Xu X, Zhai Z. Clinical implications of aberrant PD-1 expression for acute leukemia prognosis. Eur J Med Res. 2023;28(1):383.","journal-title":"Eur J Med Res"},{"issue":"5","key":"3869_CR41","doi-asserted-by":"publisher","first-page":"3044","DOI":"10.3390\/curroncol29050247","volume":"29","author":"Y Shiravand","year":"2022","unstructured":"Shiravand Y, Khodadadi F, Kashani SMA, Hosseini-Fard SR, Hosseini S, Sadeghirad H, et al. Immune checkpoint inhibitors in cancer therapy. Curr Oncol. 2022;29(5):3044\u201360.","journal-title":"Curr Oncol"},{"issue":"2","key":"3869_CR42","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1080\/10428194.2022.2148212","volume":"64","author":"S Assouline","year":"2023","unstructured":"Assouline S, Michaelis LC, Othus M, Hay AE, Walter RB, Jacoby MA, et al. A randomized phase II\/III study of \u2018novel therapeutics\u2019 versus azacitidine in newly diagnosed patients with acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (MDS), or chronic myelomonocytic leukemia (CMML), age 60 or older: a report of the comparison of azacitidine and nivolumab to azacitidine: SWOG S1612. Leukemia Lymphoma. 2023;64(2):473\u20137.","journal-title":"Leukemia Lymphoma"},{"key":"3869_CR43","doi-asserted-by":"publisher","first-page":"1716","DOI":"10.1182\/blood-2022-157326","volume":"140","author":"H Liu","year":"2022","unstructured":"Liu H, Sharon E, Karrison TG, Zha Y, Fulton N, Streicher H, et al. Randomized phase II study to assess the role of nivolumab as single agent to eliminate minimal residual disease and maintain remission in acute myelogenous leukemia (AML) patients after chemotherapy (NCI9706 protocol; REMAIN trial). Blood. 2022;140:1716\u20139.","journal-title":"Blood"},{"key":"3869_CR44","doi-asserted-by":"publisher","first-page":"618710","DOI":"10.3389\/fimmu.2021.618710","volume":"12","author":"Z Wang","year":"2021","unstructured":"Wang Z, Chen J, Wang M, Zhang L, Yu L. One stone, two birds: the roles of Tim-3 in acute myeloid leukemia. Front Immunol. 2021;12:618710.","journal-title":"Front Immunol"},{"key":"3869_CR45","doi-asserted-by":"crossref","unstructured":"Dama P, Tang M, Fulton N, Kline J, Liu HJ. Gal9\/Tim-3 expression level is higher in AML patients who fail chemotherapy. J Immunother Cancer. 2019;7:1\u20137.","DOI":"10.1186\/s40425-019-0611-3"},{"key":"3869_CR46","doi-asserted-by":"publisher","first-page":"3677","DOI":"10.1182\/blood-2021-151455","volume":"138","author":"AM Brunner","year":"2021","unstructured":"Brunner AM, Traer E, Vey N, Scholl S, Tovar N, Porkka K, et al. Allogeneic hematopoietic cell transplantation outcomes of patients with R\/R AML or higher-risk MDS treated with the TIM-3 inhibitor MBG453 (Sabatolimab) and hypomethylating agents. Blood. 2021;138:3677.","journal-title":"Blood"},{"key":"3869_CR47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1182\/blood-2020-136855","volume":"136","author":"AM Brunner","year":"2020","unstructured":"Brunner AM, Esteve J, Porkka K, Knapper S, Vey N, Scholl S, et al. Efficacy and safety of sabatolimab (MBG453) in combination with hypomethylating agents (HMAs) in patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR-MDS): updated results from a phase 1b study. Blood. 2020;136:1\u20132.","journal-title":"Blood"},{"issue":"15","key":"3869_CR48","doi-asserted-by":"publisher","first-page":"2815","DOI":"10.1200\/JCO.22.01794","volume":"41","author":"DA Sallman","year":"2023","unstructured":"Sallman DA, Al Malki MM, Asch AS, Wang ES, Jurcic JG, Bradley TJ, et al. Magrolimab in combination with azacitidine in patients with higher-risk myelodysplastic syndromes: final results of a phase Ib study. J Clin Oncol. 2023;41(15):2815\u201326.","journal-title":"J Clin Oncol"},{"issue":"3","key":"3869_CR49","doi-asserted-by":"publisher","first-page":"43","DOI":"10.3390\/antib8030043","volume":"8","author":"Q Wang","year":"2019","unstructured":"Wang Q, Chen Y, Park J, Liu X, Hu Y, Wang T, et al. Design and production of bispecific antibodies. Antibodies. 2019;8(3):43.","journal-title":"Antibodies"},{"key":"3869_CR50","doi-asserted-by":"publisher","first-page":"195","DOI":"10.2147\/DDDT.S151282","volume":"12","author":"SE Sedykh","year":"2018","unstructured":"Sedykh SE, Prinz VV, Buneva VN, Nevinsky GA. Bispecific antibodies: design, therapy, perspectives. Drug Des Dev Ther. 2018;12:195\u2013208.","journal-title":"Drug Design, Development and Therapy"},{"issue":"9","key":"3869_CR51","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1056\/NEJMoa1609783","volume":"376","author":"H Kantarjian","year":"2017","unstructured":"Kantarjian H, Stein A, G\u00f6kbuget N, Fielding AK, Schuh AC, Ribera J-M, et al. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N Engl J Med. 2017;376(9):836\u201347.","journal-title":"N Engl J Med"},{"key":"3869_CR52","doi-asserted-by":"crossref","unstructured":"van der Sluis IM, de Lorenzo P, Kotecha RS, Attarbaschi A, Escherich G, Nysom K, et al. Blinatumomab added to chemotherapy in infant lymphoblastic leukemia. N Engl J Med. 2023;388(17):1572\u201381.","DOI":"10.1056\/NEJMoa2214171"},{"key":"3869_CR53","doi-asserted-by":"crossref","unstructured":"G\u00f6kbuget N, Dombret H, Bonifacio M, Reichle A, Graux C, Faul C, et al. Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia. Blood J Am Soc Hematol. 2018;131(14):1522\u201331.","DOI":"10.1182\/blood-2017-08-798322"},{"issue":"7","key":"3869_CR54","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1080\/14712598.2019.1623200","volume":"19","author":"PF van Loo","year":"2019","unstructured":"van Loo PF, Hangalapura BN, Thordardottir S, Gibbins JD, Veninga H, Hendriks LJA, et al. MCLA-117, a CLEC12AxCD3 bispecific antibody targeting a leukaemic stem cell antigen, induces T cell-mediated AML blast lysis. Expert Opin Biol Ther. 2019;19(7):721\u201333.","journal-title":"Expert Opin Biol Ther"},{"key":"3869_CR55","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1182\/blood-2023-187721","volume":"142","author":"GSG Murthy","year":"2023","unstructured":"Murthy GSG, Leonard JT, Badar T, Yi CYA, Duvall AS, Shah BD, et al. A phase 1 study of CD38-bispecific antibody (XmAb18968) for patients with CD38 expressing relapsed\/refractory acute myeloid leukemia. Blood. 2023;142:1541.","journal-title":"Blood"},{"key":"3869_CR56","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1182\/blood.V130.Suppl_1.637.637","volume":"130","author":"GL Uy","year":"2017","unstructured":"Uy GL, Godwin J, Rettig MP, Vey N, Foster M, Arellano ML, et al. Preliminary results of a phase 1 study of flotetuzumab, a CD123 x CD3 bispecific Dart\u00ae protein, in patients with relapsed\/refractory acute myeloid leukemia and myelodysplastic syndrome. Blood. 2017;130:637.","journal-title":"Blood"},{"issue":"5","key":"3869_CR57","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1002\/jcb.25782","volume":"118","author":"N Khera","year":"2017","unstructured":"Khera N, Rajput S. Therapeutic potential of small molecule inhibitors. J Cell Biochem. 2017;118(5):959\u201361.","journal-title":"J Cell Biochem"},{"issue":"1","key":"3869_CR58","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41392-020-00451-w","volume":"6","author":"L Zhong","year":"2021","unstructured":"Zhong L, Li Y, Xiong L, Wang W, Wu M, Yuan T, et al. Small molecules in targeted cancer therapy: advances, challenges, and future perspectives. Signal Transduct Target Ther. 2021;6(1):1\u201348.","journal-title":"Signal Transduct Target Ther"},{"key":"3869_CR59","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/bs.ctdb.2014.11.005","volume":"111","author":"KA Fantauzzo","year":"2015","unstructured":"Fantauzzo KA, Soriano P. Receptor tyrosine kinase signaling: regulating neural crest development one phosphate at a time. Curr Top Dev Biol. 2015;111:135\u201382.","journal-title":"Curr Top Dev Biol"},{"issue":"1","key":"3869_CR60","doi-asserted-by":"publisher","first-page":"4147","DOI":"10.1038\/s41467-020-17666-8","volume":"11","author":"S Rai","year":"2020","unstructured":"Rai S, Tanaka H, Suzuki M, Espinoza JL, Kumode T, Tanimura A, et al. Chlorpromazine eliminates acute myeloid leukemia cells by perturbing subcellular localization of FLT3-ITD and KIT-D816V. Nat Commun. 2020;11(1):4147.","journal-title":"Nat Commun"},{"issue":"23","key":"3869_CR61","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","volume":"374","author":"E Papaemmanuil","year":"2016","unstructured":"Papaemmanuil E, Gerstung M, Bullinger L, Gaidzik VI, Paschka P, Roberts ND, et al. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med. 2016;374(23):2209\u201321.","journal-title":"N Engl J Med"},{"issue":"32","key":"3869_CR62","doi-asserted-by":"publisher","first-page":"52026","DOI":"10.18632\/oncotarget.19036","volume":"8","author":"EL Weisberg","year":"2017","unstructured":"Weisberg EL, Puissant A, Stone R, Sattler M, Buhrlage SJ, Yang J, et al. Characterization of midostaurin as a dual inhibitor of FLT3 and SYK and potentiation of FLT3 inhibition against FLT3-ITD-driven leukemia harboring activated SYK kinase. Oncotarget. 2017;8(32):52026.","journal-title":"Oncotarget"},{"key":"3869_CR63","doi-asserted-by":"publisher","first-page":"115977","DOI":"10.1016\/j.ejmech.2023.115977","volume":"264","author":"X Wang","year":"2024","unstructured":"Wang X, DeFilippis RA, Weldemichael T, Gunaganti N, Tran P, Leung Y-K, et al. An imidazo [1, 2-a] pyridine-pyridine derivative potently inhibits FLT3-ITD and FLT3-ITD secondary mutants, including gilteritinib-resistant FLT3-ITD\/F691L. Eur J Med Chem. 2024;264:115977.","journal-title":"Eur J Med Chem"},{"issue":"17","key":"3869_CR64","doi-asserted-by":"publisher","first-page":"4950","DOI":"10.1182\/bloodadvances.2023010392","volume":"7","author":"AB Halpern","year":"2023","unstructured":"Halpern AB, Rodr\u00edguez-Arbol\u00ed E, Othus M, Garcia K-LA, Percival M-EM, Cassaday RD, et al. Phase 1\/2 study of sorafenib added to cladribine, high-dose cytarabine, G-CSF, and mitoxantrone in untreated AML. Blood Adv. 2023;7(17):4950\u201361.","journal-title":"Blood Adv"},{"issue":"47","key":"3869_CR65","doi-asserted-by":"publisher","first-page":"82897","DOI":"10.18632\/oncotarget.19970","volume":"8","author":"KM Kampa-Schittenhelm","year":"2017","unstructured":"Kampa-Schittenhelm KM, Frey J, Haeusser LA, Illing B, Pavlovsky AA, Blumenstock G, Schittenhelm MM. Crenolanib is a type I tyrosine kinase inhibitor that inhibits mutant KIT D816 isoforms prevalent in systemic mastocytosis and core binding factor leukemia. Oncotarget. 2017;8(47):82897.","journal-title":"Oncotarget"},{"issue":"3\u20134","key":"3869_CR66","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.vetimm.2013.01.003","volume":"152","author":"M Giantin","year":"2013","unstructured":"Giantin M, Aresu L, Aric\u00f2 A, Gelain ME, Riondato F, Martini V, et al. Evaluation of tyrosine-kinase receptor c-KIT (c-KIT) mutations, mRNA and protein expression in canine leukemia: might c-KIT represent a therapeutic target? Vet Immunol Immunopathol. 2013;152(3\u20134):325\u201332.","journal-title":"Vet Immunol Immunopathol"},{"issue":"3","key":"3869_CR67","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1001\/jamaoncol.2019.5868","volume":"6","author":"S Shen","year":"2020","unstructured":"Shen S, Chen X, Cai J, Yu J, Gao J, Hu S, et al. Effect of dasatinib vs imatinib in the treatment of pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: a randomized clinical trial. JAMA Oncol. 2020;6(3):358\u201366.","journal-title":"JAMA Oncol"},{"issue":"5","key":"3869_CR68","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1016\/j.ccell.2019.04.006","volume":"35","author":"BD Smith","year":"2019","unstructured":"Smith BD, Kaufman MD, Lu W-P, Gupta A, Leary CB, Wise SC, et al. Ripretinib (DCC-2618) is a switch control kinase inhibitor of a broad spectrum of oncogenic and drug-resistant KIT and PDGFRA variants. Cancer Cell. 2019;35(5):738\u201351.","journal-title":"Cancer Cell"},{"key":"3869_CR69","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12943-018-0788-y","volume":"17","author":"KS Siveen","year":"2018","unstructured":"Siveen KS, Prabhu KS, Achkar IW, Kuttikrishnan S, Shyam S, Khan AQ, et al. Role of non receptor tyrosine kinases in hematological malignances and its targeting by natural products. Mol Cancer. 2018;17:1\u201321.","journal-title":"Mol Cancer"},{"key":"3869_CR70","doi-asserted-by":"publisher","first-page":"155161","DOI":"10.1016\/j.prp.2024.155161","volume":"254","author":"M El-Tanani","year":"2024","unstructured":"El-Tanani M, Nsairat H, Matalka II, Lee YF, Rizzo M, Aljabali AA, et al. The impact of the BCR-ABL oncogene in the pathology and treatment of chronic myeloid leukemia. Pathol Res Pract. 2024;254:155161.","journal-title":"Pathol Res Pract"},{"key":"3869_CR71","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13045-018-0624-2","volume":"11","author":"F Rossari","year":"2018","unstructured":"Rossari F, Minutolo F, Orciuolo E. Past, present, and future of Bcr-Abl inhibitors: from chemical development to clinical efficacy. J Hematol Oncol. 2018;11:1\u201314.","journal-title":"J Hematol Oncol"},{"issue":"11","key":"3869_CR72","first-page":"2665","volume":"116","author":"H Kantarjian","year":"2010","unstructured":"Kantarjian H, Coutre PL, Cortes J, Pinilla-Ibarz J, Nagler A, Hochhaus A, et al. Phase 1 study of INNO-406, a dual Abl\/Lyn kinase inhibitor, in Philadelphia chromosome-positive leukemias after imatinib resistance or intolerance. Cancer Interdiscipl Int J Am Cancer Soc. 2010;116(11):2665\u201372.","journal-title":"Cancer Interdiscipl Int J Am Cancer Soc"},{"key":"3869_CR73","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.4783","author":"E Jabbour","year":"2024","unstructured":"Jabbour E, Kantarjian HM, Aldoss I, Montesinos P, Leonard JT, G\u00f3mez-Almaguer D, et al. Ponatinib vs imatinib in frontline Philadelphia chromosome\u2013positive acute lymphoblastic leukemia: a randomized clinical trial. JAMA. 2024. https:\/\/doi.org\/10.1001\/jama.2024.4783.","journal-title":"JAMA"},{"issue":"8","key":"3869_CR74","first-page":"1229","volume":"123","author":"SA Rushworth","year":"2014","unstructured":"Rushworth SA, Murray MY, Zaitseva L, Bowles KM, MacEwan DJ. Identification of Bruton\u2019s tyrosine kinase as a therapeutic target in acute myeloid leukemia. Blood J Am Soc Hematol. 2014;123(8):1229\u201338.","journal-title":"Blood J Am Soc Hematol"},{"issue":"1","key":"3869_CR75","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s12943-018-0779-z","volume":"17","author":"S Pal Singh","year":"2018","unstructured":"Pal Singh S, Dammeijer F, Hendriks RW. Role of Bruton\u2019s tyrosine kinase in B cells and malignancies. Mol Cancer. 2018;17(1):57.","journal-title":"Mol Cancer"},{"issue":"7","key":"3869_CR76","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1158\/1535-7163.MCT-21-0832","volume":"21","author":"WG Rice","year":"2022","unstructured":"Rice WG, Howell SB, Zhang H, Rastgoo N, Local A, Kurtz SE, et al. Luxeptinib (CG-806) targets FLT3 and clusters of kinases operative in acute myeloid leukemia. Mol Cancer Ther. 2022;21(7):1125\u201335.","journal-title":"Mol Cancer Ther"},{"issue":"5","key":"3869_CR77","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1200\/JCO.22.00510","volume":"41","author":"P Hillmen","year":"2023","unstructured":"Hillmen P, Eichhorst B, Brown JR, Lamanna N, O\u2019Brien SM, Tam CS, et al. Zanubrutinib versus ibrutinib in relapsed\/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma: interim analysis of a randomized phase III trial. J Clin Oncol. 2023;41(5):1035\u201345.","journal-title":"J Clin Oncol"},{"issue":"S3","key":"3869_CR78","doi-asserted-by":"publisher","first-page":"e21928ec","DOI":"10.1097\/01.HS9.0000974536.21928.ec","volume":"7","author":"S Yang","year":"2023","unstructured":"Yang S, Huang H, Zhou K, Zhao X, Han Y-Q, Lindong L, et al. PB1929: efficacy and safety of acalabrutinib in chinese patients with relapsed\/refractory chronic lymphocytic leukemia: an open-label, multicenter phase 1\/2 trial. HemaSphere. 2023;7(S3):e21928ec.","journal-title":"HemaSphere"},{"issue":"1","key":"3869_CR79","first-page":"e127352","volume":"21","author":"M Soltanshahi","year":"2022","unstructured":"Soltanshahi M, Taghiloo S, Asgarian-Omran H. Expression modulation of immune checkpoint molecules by ibrutinib and everolimus through STAT3 in MCF-7 breast cancer cells. Iran J Pharm Res IJPR. 2022;21(1):e127352.","journal-title":"Iran J Pharm Res IJPR"},{"issue":"12","key":"3869_CR80","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1093\/carcin\/bgab075","volume":"42","author":"HE Sabaawy","year":"2021","unstructured":"Sabaawy HE, Ryan BM, Khiabanian H, Pine SR. JAK\/STAT of all trades: linking inflammation with cancer development, tumor progression and therapy resistance. Carcinogenesis. 2021;42(12):1411\u20139.","journal-title":"Carcinogenesis"},{"issue":"13","key":"3869_CR81","doi-asserted-by":"publisher","first-page":"6844","DOI":"10.3390\/ijms25136844","volume":"25","author":"KJ Zi\u0119tara","year":"2024","unstructured":"Zi\u0119tara KJ, Wr\u00f3blewska K, Zaj\u0105czkowska M, Tacza\u0142a J, Lejman M. The role of the JAK\u2013STAT pathway in childhood B-cell acute lymphoblastic leukemia. Int J Mol Sci. 2024;25(13):6844.","journal-title":"Int J Mol Sci"},{"issue":"9","key":"3869_CR82","first-page":"4809","volume":"111","author":"Z Xiang","year":"2008","unstructured":"Xiang Z, Zhao Y, Mitaksov V, Fremont DH, Kasai Y, Molitoris A, et al. Identification of somatic JAK1 mutations in patients with acute myeloid leukemia. Blood J Am Soc Hematol. 2008;111(9):4809\u201312.","journal-title":"Blood J Am Soc Hematol"},{"issue":"5","key":"3869_CR83","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1007\/s11899-022-00671-7","volume":"17","author":"JA Waksal","year":"2022","unstructured":"Waksal JA, Mascarenhas J. Novel therapies in myelofibrosis: beyond JAK inhibitors. Curr Hematol Malig Rep. 2022;17(5):140\u201354.","journal-title":"Curr Hematol Malig Rep"},{"issue":"3","key":"3869_CR84","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.clml.2014.08.003","volume":"15","author":"N Pemmaraju","year":"2015","unstructured":"Pemmaraju N, Kantarjian H, Kadia T, Cortes J, Borthakur G, Newberry K, et al. A phase I\/II study of the Janus kinase (JAK) 1 and 2 inhibitor ruxolitinib in patients with relapsed or refractory acute myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2015;15(3):171\u20136.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"3869_CR85","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40364-018-0123-1","volume":"6","author":"Y Ling","year":"2018","unstructured":"Ling Y, Xie Q, Zhang Z, Zhang H. Protein kinase inhibitors for acute leukemia. Biomark Res. 2018;6:1\u20137.","journal-title":"Biomark Res"},{"key":"3869_CR86","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.phrs.2018.11.035","volume":"139","author":"R Roskoski Jr","year":"2019","unstructured":"Roskoski R Jr. Cyclin-dependent protein serine\/threonine kinase inhibitors as anticancer drugs. Pharmacol Res. 2019;139:471\u201388.","journal-title":"Pharmacol Res"},{"issue":"13","key":"3869_CR87","doi-asserted-by":"publisher","first-page":"3251","DOI":"10.1158\/1078-0432.CCR-16-3157","volume":"23","author":"D Tripathy","year":"2017","unstructured":"Tripathy D, Bardia A, Sellers WR. Ribociclib (LEE011): mechanism of action and clinical impact of this selective cyclin-dependent kinase 4\/6 inhibitor in various solid tumors. Clin Cancer Res. 2017;23(13):3251\u201362.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"3869_CR88","first-page":"307","volume":"9","author":"JE Karp","year":"2003","unstructured":"Karp JE, Ross DD, Yang W, Tidwell ML, Wei Y, Greer J, et al. Timed sequential therapy of acute leukemia with flavopiridol: in vitro model for a phase I clinical trial. Clin Cancer Res. 2003;9(1):307\u201315.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"3869_CR89","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1158\/1078-0432.CCR-20-2649","volume":"27","author":"JF Zeidner","year":"2021","unstructured":"Zeidner JF, Lee DJ, Frattini M, Fine GD, Costas J, Kolibaba K, et al. Phase I study of alvocidib followed by 7+ 3 (cytarabine+ daunorubicin) in newly diagnosed acute myeloid leukemia. Clin Cancer Res. 2021;27(1):60\u20139.","journal-title":"Clin Cancer Res"},{"key":"3869_CR90","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1182\/blood-2020-139494","volume":"136","author":"A Nazha","year":"2020","unstructured":"Nazha A, Mukherjee S, Siebenaller C, Waldron M, Parsons E, Thomas J, et al. A phase I\/II trial of CPX-351+ palbociclib in patients with acute myeloid leukemia. Blood. 2020;136:13\u20134.","journal-title":"Blood"},{"issue":"21","key":"3869_CR91","doi-asserted-by":"publisher","first-page":"5297","DOI":"10.3390\/cancers15215297","volume":"15","author":"W Wiese","year":"2023","unstructured":"Wiese W, Barczuk J, Racinska O, Siwecka N, Rozpedek-Kaminska W, Slupianek A, et al. PI3K\/Akt\/mTOR signaling pathway in blood malignancies\u2014new therapeutic possibilities. Cancers. 2023;15(21):5297.","journal-title":"Cancers"},{"issue":"8","key":"3869_CR92","doi-asserted-by":"publisher","first-page":"2907","DOI":"10.3390\/ijms21082907","volume":"21","author":"I Nepstad","year":"2020","unstructured":"Nepstad I, Hatfield KJ, Gr\u00f8nnings\u00e6ter IS, Reikvam H. The PI3K-Akt-mTOR signaling pathway in human acute myeloid leukemia (AML) cells. Int J Mol Sci. 2020;21(8):2907.","journal-title":"Int J Mol Sci"},{"issue":"4","key":"3869_CR93","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1158\/1078-0432.CCR-15-2869","volume":"23","author":"Y Pikman","year":"2017","unstructured":"Pikman Y, Alexe G, Roti G, Conway AS, Furman A, Lee ES, et al. Synergistic drug combinations with a CDK4\/6 inhibitor in T-cell acute lymphoblastic leukemia. Clin Cancer Res. 2017;23(4):1012\u201324.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"3869_CR94","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1111\/j.1365-2141.2011.08940.x","volume":"156","author":"S Amadori","year":"2012","unstructured":"Amadori S, Stasi R, Martelli AM, Venditti A, Meloni G, Pane F, et al. Temsirolimus, an mTOR inhibitor, in combination with lower-dose clofarabine as salvage therapy for older patients with acute myeloid leukaemia: results of a phase II GIMEMA study (AML-1107). Br J Haematol. 2012;156(2):205\u201312.","journal-title":"Br J Haematol"},{"issue":"2","key":"3869_CR95","first-page":"178","volume":"21","author":"S Taghiloo","year":"2022","unstructured":"Taghiloo S, Norozi S, Asgarian-Omran H. The effects of Pi3k\/Akt\/Mtor signaling pathway inhibitors on the expression of immune checkpoint ligands in acute myeloid leukemia cell line. Iran J Allergy Asthma Immunol. 2022;21(2):178\u201388.","journal-title":"Iran J Allergy Asthma Immunol"},{"issue":"1","key":"3869_CR96","first-page":"58","volume":"19","author":"S Taghiloo","year":"2022","unstructured":"Taghiloo S, Ajami A, Alizadeh-Navaei R, Zaboli E, Asgarian-Omran H. Treatment by PI3K\/mTOR inhibitor BEZ235 combined with TLR-7\/8 agonist interfere with immune evasion mechanisms of WEHI-3 mouse leukemia cells. Iran J Immunol. 2022;19(1):58\u201370.","journal-title":"Iran J Immunol"},{"key":"3869_CR97","doi-asserted-by":"publisher","first-page":"111211","DOI":"10.1016\/j.intimp.2023.111211","volume":"125","author":"S Taghiloo","year":"2023","unstructured":"Taghiloo S, Ajami A, Alizadeh-Navaei R, Asgarian-Omran H. Combination therapy of acute myeloid leukemia by dual PI3K\/mTOR inhibitor BEZ235 and TLR-7\/8 agonist R848 in murine model. Int Immunopharmacol. 2023;125:111211.","journal-title":"Int Immunopharmacol"},{"issue":"8","key":"3869_CR98","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1038\/nrg.2016.59","volume":"17","author":"CD Allis","year":"2016","unstructured":"Allis CD, Jenuwein T. The molecular hallmarks of epigenetic control. Nat Rev Genet. 2016;17(8):487\u2013500.","journal-title":"Nat Rev Genet"},{"issue":"5","key":"3869_CR99","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.cancergen.2014.10.005","volume":"208","author":"M Chopra","year":"2015","unstructured":"Chopra M, Bohlander SK. Disturbing the histone code in leukemia: translocations and mutations affecting histone methyl transferases. Cancer Genet. 2015;208(5):192\u2013205.","journal-title":"Cancer Genet"},{"issue":"7","key":"3869_CR100","doi-asserted-by":"publisher","first-page":"1972","DOI":"10.3390\/cancers12071972","volume":"12","author":"A Lonetti","year":"2020","unstructured":"Lonetti A, Indio V, Laginestra MA, Tarantino G, Chiarini F, Astolfi A, et al. Inhibition of methyltransferase DOT1L sensitizes to sorafenib treatment AML cells irrespective of MLL-rearrangements: a novel therapeutic strategy for pediatric AML. Cancers. 2020;12(7):1972.","journal-title":"Cancers"},{"key":"3869_CR101","doi-asserted-by":"publisher","first-page":"110144","DOI":"10.1016\/j.cellsig.2021.110144","volume":"87","author":"X Yang","year":"2021","unstructured":"Yang X, Wan M, Yu F, Wu X. Histone methyltransferase EZH2 epigenetically affects CCNA1 expression in acute myeloid leukemia. Cell Signal. 2021;87:110144.","journal-title":"Cell Signal"},{"issue":"24","key":"3869_CR102","first-page":"2661","volume":"131","author":"EM Stein","year":"2018","unstructured":"Stein EM, Garcia-Manero G, Rizzieri DA, Tibes R, Berdeja JG, Savona MR, et al. The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemia. Blood J Am Soc Hematol. 2018;131(24):2661\u20139.","journal-title":"Blood J Am Soc Hematol"},{"key":"3869_CR103","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/978-1-4939-2474-5_7","volume-title":"Chromatin protocols","author":"L Peng","year":"2015","unstructured":"Peng L, Yuan Z, Seto E. Histone deacetylase activity assay. In: Chellappan S, editor. Chromatin protocols. New York: Humana Press; 2015. p. 95\u2013108."},{"key":"3869_CR104","first-page":"166","volume":"3","author":"K Hyun-Chung","year":"2011","unstructured":"Hyun-Chung K, Suk-Chul B. HDAC inhibitors as anti-cancer drugs. Am J Transl Res. 2011;3:166\u201379.","journal-title":"Am J Transl Res"},{"issue":"1","key":"3869_CR105","doi-asserted-by":"publisher","first-page":"e25","DOI":"10.3324\/haematol.2017.172411","volume":"103","author":"RF Schlenk","year":"2018","unstructured":"Schlenk RF, Krauter J, Raffoux E, Kreuzer K-A, Schaich M, Noens L, et al. Panobinostat monotherapy and combination therapy in patients with acute myeloid leukemia: results from two clinical trials. Haematologica. 2018;103(1):e25.","journal-title":"Haematologica"},{"issue":"10","key":"3869_CR106","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.3324\/haematol.2009.009217","volume":"94","author":"EW Schaefer","year":"2009","unstructured":"Schaefer EW, Loaiza-Bonilla A, Juckett M, DiPersio JF, Roy V, Slack J, et al. A phase 2 study of vorinostat in acute myeloid leukemia. Haematologica. 2009;94(10):1375.","journal-title":"Haematologica"},{"issue":"10","key":"3869_CR107","doi-asserted-by":"publisher","first-page":"2301","DOI":"10.3109\/10428194.2013.877134","volume":"55","author":"MH Kirschbaum","year":"2014","unstructured":"Kirschbaum MH, Foon KA, Frankel P, Ruel C, Pulone B, Tuscano JM, Newman EM. A phase 2 study of belinostat (PXD101) in patients with relapsed or refractory acute myeloid leukemia or patients over the age of 60 with newly diagnosed acute myeloid leukemia: a California Cancer Consortium Study. Leuk Lymphoma. 2014;55(10):2301\u20134.","journal-title":"Leuk Lymphoma"},{"issue":"9","key":"3869_CR108","doi-asserted-by":"publisher","first-page":"2482","DOI":"10.1038\/s41375-021-01309-y","volume":"35","author":"GC Issa","year":"2021","unstructured":"Issa GC, Ravandi F, DiNardo CD, Jabbour E, Kantarjian HM, Andreeff M. Therapeutic implications of menin inhibition in acute leukemias. Leukemia. 2021;35(9):2482\u201395.","journal-title":"Leukemia"},{"issue":"2","key":"3869_CR109","doi-asserted-by":"publisher","first-page":"244","DOI":"10.3390\/hematolrep16020024","volume":"16","author":"A Candoni","year":"2024","unstructured":"Candoni A, Coppola G. A 2024 update on menin inhibitors. A new class of target agents against KMT2A-rearranged and NPM1-mutated acute myeloid leukemia. Hematol Rep. 2024;16(2):244\u201354.","journal-title":"Hematol Rep"},{"key":"3869_CR110","doi-asserted-by":"publisher","first-page":"2907","DOI":"10.1182\/blood-2023-189762","volume":"142","author":"I Aldoss","year":"2023","unstructured":"Aldoss I, Issa GC, Thirman MJ, DiPersio J, Arellano M, Blachly JS, et al. Revumenib monotherapy in patients with relapsed\/refractory KMT2Ar acute leukemias: efficacy and safety results from the Augment-101 phase 1\/2 study. Blood. 2023;142:2907.","journal-title":"Blood"},{"issue":"Supplement 1","key":"3869_CR111","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1182\/blood-2022-167412","volume":"140","author":"HP Erba","year":"2022","unstructured":"Erba HP, Fathi AT, Issa GC, Altman JK, Montesinos P, Patnaik MM, et al. Update on a phase 1\/2 first-in-human study of the menin-KMT2A (MLL) inhibitor ziftomenib (KO-539) in patients with relapsed or refractory acute myeloid leukemia. Blood. 2022;140(Supplement 1):153\u20136.","journal-title":"Blood"},{"issue":"8","key":"3869_CR112","doi-asserted-by":"publisher","first-page":"1674","DOI":"10.1038\/s41375-024-02312-9","volume":"38","author":"H Miao","year":"2024","unstructured":"Miao H, Chen D, Ropa J, Purohit T, Kim E, Sulis M-L, et al. Combination of menin and kinase inhibitors as an effective treatment for leukemia with NUP98 translocations. Leukemia. 2024;38(8):1674\u201387.","journal-title":"Leukemia"},{"issue":"7","key":"3869_CR113","doi-asserted-by":"publisher","first-page":"794","DOI":"10.2174\/1871520623666221025145320","volume":"23","author":"SS Fard","year":"2023","unstructured":"Fard SS, Kouchaki S, Salimian Z, Sotoudeh M, Mousavi SA, Alimoghaddam K, Ghaffari SH. Overexpression of bromodomain and extraterminal domain is associated with progression, metastasis and unfavorable outcomes: highlighting prognostic and therapeutic value of the BET protein family in gastric cancer. Anti-Cancer Agents Med Chem. 2023;23(7):794\u2013806.","journal-title":"Anti-Cancer Agents Med Chem"},{"issue":"19","key":"3869_CR114","doi-asserted-by":"publisher","first-page":"17698","DOI":"10.18632\/oncotarget.4131","volume":"6","author":"M-M Coud\u00e9","year":"2015","unstructured":"Coud\u00e9 M-M, Braun T, Berrou J, Dupont M, Bertrand S, Masse A, et al. BET inhibitor OTX015 targets BRD2 and BRD4 and decreases c-MYC in acute leukemia cells. Oncotarget. 2015;6(19):17698.","journal-title":"Oncotarget"},{"issue":"21","key":"3869_CR115","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1182\/blood.V124.21.117.117","volume":"124","author":"H Dombret","year":"2014","unstructured":"Dombret H, Preudhomme C, Berthon C, Raffoux E, Thomas X, Vey N, et al. A phase 1 study of the BET-bromodomain inhibitor OTX015 in patients with advanced acute leukemia. Blood. 2014;124(21):117.","journal-title":"Blood"},{"issue":"16","key":"3869_CR116","doi-asserted-by":"publisher","first-page":"2943","DOI":"10.1002\/cncr.33590","volume":"127","author":"G Borthakur","year":"2021","unstructured":"Borthakur G, Odenike O, Aldoss I, Rizzieri DA, Prebet T, Chen C, et al. A phase 1 study of the pan-bromodomain and extraterminal inhibitor mivebresib (ABBV-075) alone or in combination with venetoclax in patients with relapsed\/refractory acute myeloid leukemia. Cancer. 2021;127(16):2943\u201353.","journal-title":"Cancer"},{"issue":"4","key":"3869_CR117","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1158\/1078-0432.CCR-22-1284","volume":"29","author":"MA Dawson","year":"2023","unstructured":"Dawson MA, Borthakur G, Huntly BJ, Karadimitris A, Alegre A, Chaidos A, et al. A phase I\/II open-label study of molibresib for the treatment of relapsed\/refractory hematologic malignancies. Clin Cancer Res. 2023;29(4):711\u201322.","journal-title":"Clin Cancer Res"},{"issue":"7","key":"3869_CR118","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1080\/10520295.2017.1367034","volume":"92","author":"Y Kim","year":"2017","unstructured":"Kim Y, Kim K, Lee S, Oh S, Park J, Lee K, et al. Expression patterns of members of the isocitrate dehydrogenase gene family in murine inner ear. Biotech Histochem. 2017;92(7):536\u201344.","journal-title":"Biotech Histochem"},{"issue":"5","key":"3869_CR119","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1182\/bloodadvances.2021004934","volume":"6","author":"JM Middeke","year":"2022","unstructured":"Middeke JM, Metzeler KH, R\u00f6llig C, Kr\u00e4mer M, Eckardt J-N, Stasik S, et al. Differential impact of IDH1\/2 mutational subclasses on outcome in adult AML: results from a large multicenter study. Blood Adv. 2022;6(5):1394\u2013405.","journal-title":"Blood Adv"},{"issue":"5","key":"3869_CR120","doi-asserted-by":"publisher","first-page":"411","DOI":"10.23736\/S0026-4806.20.07024-X","volume":"111","author":"MP Martelli","year":"2020","unstructured":"Martelli MP, Martino G, Cardinali V, Falini B, Martinelli G, Cerchione C. Enasidenib and ivosidenib in AML. Minerva Med. 2020;111(5):411\u201326.","journal-title":"Minerva Med"},{"key":"3869_CR121","first-page":"19","volume":"17","author":"S Semochkin","year":"2023","unstructured":"Semochkin S, Kim H-J, Larson RA, Koprivnikar J, Frankfurt O, Thol F, et al. Enasidenib vs conventional care in older patients with late-stage mutant-IDH2 relapsed\/refractory AML: a randomized phase 3 trial. Differentiation. 2023;17:19.","journal-title":"Differentiation"},{"issue":"16","key":"3869_CR122","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1056\/NEJMoa2117344","volume":"386","author":"P Montesinos","year":"2022","unstructured":"Montesinos P, Recher C, Vives S, Zarzycka E, Wang J, Bertani G, et al. Ivosidenib and azacitidine in IDH1-mutated acute myeloid leukemia. N Engl J Med. 2022;386(16):1519\u201331.","journal-title":"N Engl J Med"},{"issue":"7","key":"3869_CR123","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1016\/j.cell.2004.12.012","volume":"119","author":"Y Shi","year":"2004","unstructured":"Shi Y, Lan F, Matson C, Mulligan P, Whetstine JR, Cole PA, et al. Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. Cell. 2004;119(7):941\u201353.","journal-title":"Cell"},{"issue":"1","key":"3869_CR124","first-page":"151","volume":"124","author":"D Niebel","year":"2014","unstructured":"Niebel D, Kirfel J, Janzen V, H\u00f6ller T, Majores M, G\u00fctgemann I. Lysine-specific demethylase 1 (LSD1) in hematopoietic and lymphoid neoplasms. Blood J Am Soc Hematol. 2014;124(1):151\u20132.","journal-title":"Blood J Am Soc Hematol"},{"issue":"6","key":"3869_CR125","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/j.chembiol.2006.05.004","volume":"13","author":"MG Lee","year":"2006","unstructured":"Lee MG, Wynder C, Schmidt DM, McCafferty DG, Shiekhattar R. Histone H3 lysine 4 demethylation is a target of nonselective antidepressive medications. Chem Biol. 2006;13(6):563\u20137.","journal-title":"Chem Biol"},{"issue":"7","key":"3869_CR126","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1158\/1078-0432.CCR-20-4054","volume":"27","author":"MM Tayari","year":"2021","unstructured":"Tayari MM, Santos HGD, Kwon D, Bradley TJ, Thomassen A, Chen C, et al. Clinical responsiveness to all-trans retinoic acid is potentiated by LSD1 inhibition and associated with a quiescent transcriptome in myeloid malignancies. Clin Cancer Res. 2021;27(7):1893\u2013903.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"3869_CR127","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1007\/s10495-022-01780-7","volume":"28","author":"D Kaloni","year":"2023","unstructured":"Kaloni D, Diepstraten ST, Strasser A, Kelly GL. BCL-2 protein family: attractive targets for cancer therapy. Apoptosis. 2023;28(1):20\u201338.","journal-title":"Apoptosis"},{"issue":"10","key":"3869_CR128","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1158\/2159-8290.CD-16-0313","volume":"6","author":"M Konopleva","year":"2016","unstructured":"Konopleva M, Pollyea DA, Potluri J, Chyla B, Hogdal L, Busman T, et al. Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia. Cancer Discov. 2016;6(10):1106\u201317.","journal-title":"Cancer Discov"},{"key":"3869_CR129","doi-asserted-by":"publisher","first-page":"4248","DOI":"10.1182\/blood-2023-181122","volume":"142","author":"YK Valtis","year":"2023","unstructured":"Valtis YK, Geyer MB, Torres M, Grogan M, Shukla M, Stein EM, Park JH. Venetoclax in combination with pediatric-inspired chemotherapy in adults with newly diagnosed acute lymphoblastic leukemia: results of a phase I trial. Blood. 2023;142:4248.","journal-title":"Blood"},{"key":"3869_CR130","doi-asserted-by":"crossref","unstructured":"Mir-Salim D, Bhayadia R, Heckl D, Klusmann J. Testing ABT-263 for the treatment of pediatric acute myeloid leukemia. Klinische P\u00e4diatrie. 2020;232(03):e4.","DOI":"10.1055\/s-0040-1709776"},{"issue":"4","key":"3869_CR131","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1080\/10428194.2020.1845332","volume":"62","author":"S de Vos","year":"2021","unstructured":"de Vos S, Leonard JP, Friedberg JW, Zain J, Dunleavy K, Humerickhouse R, et al. Safety and efficacy of navitoclax, a BCL-2 and BCL-XL inhibitor, in patients with relapsed or refractory lymphoid malignancies: results from a phase 2a study. Leuk Lymphoma. 2021;62(4):810\u20138.","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"3869_CR132","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1158\/2643-3230.BCD-20-0007","volume":"1","author":"C Jamieson","year":"2020","unstructured":"Jamieson C, Martinelli G, Papayannidis C, Cortes JE. Hedgehog pathway inhibitors: a new therapeutic class for the treatment of acute myeloid leukemia. Blood Cancer Discov. 2020;1(2):134\u201345.","journal-title":"Blood Cancer Discov"},{"issue":"3","key":"3869_CR133","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1111\/bjh.15571","volume":"185","author":"D Bixby","year":"2019","unstructured":"Bixby D, Noppeney R, Lin TL, Cortes J, Krauter J, Yee K, et al. Safety and efficacy of vismodegib in relapsed\/refractory acute myeloid leukaemia: results of a phase Ib trial. Br J Haematol. 2019;185(3):595\u20138.","journal-title":"Br J Haematol"},{"issue":"8","key":"3869_CR134","doi-asserted-by":"publisher","first-page":"e339","DOI":"10.1016\/S2352-3026(15)00096-4","volume":"2","author":"G Martinelli","year":"2015","unstructured":"Martinelli G, Oehler VG, Papayannidis C, Courtney R, Shaik MN, Zhang X, et al. Treatment with PF-04449913, an oral smoothened antagonist, in patients with myeloid malignancies: a phase 1 safety and pharmacokinetics study. Lancet Haematol. 2015;2(8):e339\u201346.","journal-title":"Lancet Haematol"},{"issue":"4","key":"3869_CR135","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.amsu.2014.09.001","volume":"3","author":"JK Liu","year":"2014","unstructured":"Liu JK. The history of monoclonal antibody development\u2013progress, remaining challenges and future innovations. Ann Med Surg. 2014;3(4):113\u20136.","journal-title":"Ann Med Surg"},{"issue":"10","key":"3869_CR136","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1634\/theoncologist.2017-0167","volume":"22","author":"JJ Hendrikx","year":"2017","unstructured":"Hendrikx JJ, Haanen JB, Voest EE, Schellens JH, Huitema AD, Beijnen JH. Fixed dosing of monoclonal antibodies in oncology. Oncologist. 2017;22(10):1212\u201321.","journal-title":"Oncologist"},{"issue":"4","key":"3869_CR137","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/nrd3003","volume":"9","author":"TT Hansel","year":"2010","unstructured":"Hansel TT, Kropshofer H, Singer T, Mitchell JA, George AJ. The safety and side effects of monoclonal antibodies. Nat Rev Drug Discov. 2010;9(4):325\u201338.","journal-title":"Nat Rev Drug Discov"},{"key":"3869_CR138","doi-asserted-by":"publisher","first-page":"204062071989989","DOI":"10.1177\/2040620719899897","volume":"11","author":"T Jain","year":"2020","unstructured":"Jain T, Litzow MR. Management of toxicities associated with novel immunotherapy agents in acute lymphoblastic leukemia. Ther Adv Hematol. 2020;11:2040620719899897.","journal-title":"Ther Adv Hematol"},{"issue":"3","key":"3869_CR139","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1007\/s11739-023-03222-x","volume":"18","author":"M Bahap-Kara","year":"2023","unstructured":"Bahap-Kara M, Duran E, Bayraktar-Ekincioglu A, Karadag O. Interchangeability and adverse events in originator-rituximab and its biosimilar (CT-P10) among rheumatic patients: a real-life experience. Intern Emerg Med. 2023;18(3):791\u20139.","journal-title":"Intern Emerg Med"},{"issue":"1","key":"3869_CR140","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s40780-024-00334-0","volume":"10","author":"H Nishiura","year":"2024","unstructured":"Nishiura H, Takahashi M, Mori K, Sugimoto T, Emoto M, Nakamura Y. Patients with infusion-related reactions on fixed-dose rituximab treatment have higher body surface area than those without infusion-related reactions in adults with frequently relapsing minimal change nephrotic syndrome: a retrospective study. J Pharm Health Care Sci. 2024;10(1):12.","journal-title":"J Pharm Health Care Sci"},{"key":"3869_CR141","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13045-020-00975-2","volume":"13","author":"JE Cortes","year":"2020","unstructured":"Cortes JE, de Lima M, Dombret H, Estey EH, Giralt SA, Montesinos P, et al. Prevention, recognition, and management of adverse events associated with gemtuzumab ozogamicin use in acute myeloid leukemia. J Hematol Oncol. 2020;13:1\u20138.","journal-title":"J Hematol Oncol"},{"key":"3869_CR142","doi-asserted-by":"publisher","first-page":"175628641879986","DOI":"10.1177\/1756286418799864","volume":"11","author":"MC Dalakas","year":"2018","unstructured":"Dalakas MC. Neurological complications of immune checkpoint inhibitors: what happens when you \u2018take the brakes off\u2019the immune system. Ther Adv Neurol Disord. 2018;11:1756286418799864.","journal-title":"Ther Adv Neurol Disord"},{"key":"3869_CR143","doi-asserted-by":"publisher","first-page":"100810","DOI":"10.1016\/j.blre.2021.100810","volume":"49","author":"AP Longhitano","year":"2021","unstructured":"Longhitano AP, Slavin MA, Harrison SJ, Teh BW. Bispecific antibody therapy, its use and risks for infection: Bridging the knowledge gap. Blood Rev. 2021;49:100810.","journal-title":"Blood Rev"},{"issue":"4","key":"3869_CR144","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1586\/17474086.2014.932687","volume":"7","author":"M Al-Hussaini","year":"2014","unstructured":"Al-Hussaini M, DiPersio JF. Small molecule inhibitors in acute myeloid leukemia: from the bench to the clinic. Expert Rev Hematol. 2014;7(4):439\u201364.","journal-title":"Expert Rev Hematol"},{"issue":"1","key":"3869_CR145","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1002\/cpt.552","volume":"101","author":"SA Brown","year":"2017","unstructured":"Brown SA, Nhola L, Herrmann J. Cardiovascular toxicities of small molecule tyrosine kinase inhibitors: an opportunity for systems-based approaches. Clin Pharmacol Ther. 2017;101(1):65\u201380.","journal-title":"Clin Pharmacol Ther"},{"issue":"7","key":"3869_CR146","doi-asserted-by":"publisher","first-page":"e2120165","DOI":"10.1001\/jamanetworkopen.2021.20165","volume":"4","author":"Z Wang","year":"2021","unstructured":"Wang Z, Wang X, Wang Z, Feng Y, Jia Y, Jiang L, et al. Comparison of hepatotoxicity associated with new BCR-ABL tyrosine kinase inhibitors vs imatinib among patients with chronic myeloid leukemia: a systematic review and meta-analysis. JAMA Netw Open. 2021;4(7):e2120165.","journal-title":"JAMA Netw Open"},{"key":"3869_CR147","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s11899-016-0309-2","volume":"11","author":"L Caldemeyer","year":"2016","unstructured":"Caldemeyer L, Dugan M, Edwards J, Akard L. Long-term side effects of tyrosine kinase inhibitors in chronic myeloid leukemia. Curr Hematol Malig Rep. 2016;11:71\u20139.","journal-title":"Curr Hematol Malig Rep"},{"issue":"4","key":"3869_CR148","first-page":"113","volume":"12","author":"A P\u0142u\u017ca\u0144ski","year":"2016","unstructured":"P\u0142u\u017ca\u0144ski A, Pi\u00f3rek A. Side effects of tyrosine kinase inhibitors\u2014management guidelines. Oncol Clin Pract. 2016;12(4):113\u20138.","journal-title":"Oncol Clin Pract"},{"issue":"4","key":"3869_CR149","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.hoc.2017.04.005","volume":"31","author":"G Ghiaur","year":"2017","unstructured":"Ghiaur G, Levis M. Mechanisms of resistance to FLT3 inhibitors and the role of the bone marrow microenvironment. Hematol Oncol Clin North Am. 2017;31(4):681.","journal-title":"Hematol Oncol Clin North Am"},{"issue":"1","key":"3869_CR150","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1186\/s12943-023-01827-6","volume":"22","author":"A Glaviano","year":"2023","unstructured":"Glaviano A, Foo AS, Lam HY, Yap KC, Jacot W, Jones RH, et al. PI3K\/AKT\/mTOR signaling transduction pathway and targeted therapies in cancer. Mol Cancer. 2023;22(1):138.","journal-title":"Mol Cancer"},{"issue":"4","key":"3869_CR151","first-page":"471","volume":"137","author":"Y Zhao","year":"2021","unstructured":"Zhao Y, Aldoss I, Qu C, Crawford JC, Gu Z, Allen EK, et al. Tumor-intrinsic and-extrinsic determinants of response to blinatumomab in adults with B-ALL. Blood J Am Soc Hematol. 2021;137(4):471\u201384.","journal-title":"Blood J Am Soc Hematol"},{"key":"3869_CR152","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1007\/s00262-011-1119-y","volume":"61","author":"K Garrison","year":"2012","unstructured":"Garrison K, Hahn T, Lee W-C, Ling LE, Weinberg AD, Akporiaye ET. The small molecule TGF-\u03b2 signaling inhibitor SM16 synergizes with agonistic OX40 antibody to suppress established mammary tumors and reduce spontaneous metastasis. Cancer Immunol Immunother. 2012;61:511\u201321.","journal-title":"Cancer Immunol Immunother"},{"issue":"2","key":"3869_CR153","first-page":"529","volume":"11","author":"WM Smith","year":"2019","unstructured":"Smith WM, Purvis IJ, Bomstad CN, Labak CM, Velpula KK, Tsung AJ, et al. Therapeutic targeting of immune checkpoints with small molecule inhibitors. Am J Transl Res. 2019;11(2):529.","journal-title":"Am J Transl Res"},{"issue":"4","key":"3869_CR154","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1002\/hon.3009","volume":"40","author":"M Li","year":"2022","unstructured":"Li M, Yu H, Qi F, Ye Y, Hu D, Cao J, et al. Anti-CD47 immunotherapy in combination with BCL-2 inhibitor to enhance anti-tumor activity in B-cell lymphoma. Hematol Oncol. 2022;40(4):596\u2013608.","journal-title":"Hematol Oncol"},{"issue":"1","key":"3869_CR155","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s40364-021-00291-y","volume":"9","author":"JJ Mistry","year":"2021","unstructured":"Mistry JJ, Hellmich C, Lambert A, Moore JA, Jibril A, Collins A, et al. Venetoclax and Daratumumab combination treatment demonstrates pre-clinical efficacy in mouse models of Acute Myeloid Leukemia. Biomark Res. 2021;9(1):35.","journal-title":"Biomark Res"},{"key":"3869_CR156","doi-asserted-by":"crossref","unstructured":"Yuen S, Phillips TJ, Bannerji R, Marlton P, Gritti G, Seymour JF, et al. Polatuzumab vedotin, venetoclax, and an anti-CD20 monoclonal antibody in relapsed\/refractory B-cell non-Hodgkin lymphoma. Am J Hematol. 2024. https:\/\/doi.org\/10.1002\/ajh.27341.","DOI":"10.1002\/ajh.27341"},{"key":"3869_CR157","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1182\/blood-2020-139625","volume":"136","author":"H Mu-Mosley","year":"2020","unstructured":"Mu-Mosley H, Ostermann LB, Zhao R, Bonifant CL, Gottschalk S, Velasquez MP, Andreeff M. Venetoclax enhances anti-leukemia activity of CD123-specific BiTE-secreting T-cells in AML. Blood. 2020;136:12\u20133.","journal-title":"Blood"},{"key":"3869_CR158","doi-asserted-by":"crossref","unstructured":"Koller P, Baran N, Harutyunyan K, Cavazos A, Mallampati S, Chin RL, et al. PD-1 blockade in combination with dasatinib potentiates induction of anti-acute lymphocytic leukemia immunity. J Immunother Cancer. 2023;11(10):e006619.","DOI":"10.1136\/jitc-2022-006619"},{"key":"3869_CR159","doi-asserted-by":"crossref","unstructured":"Leclercq G, Haegel H, Schneider A, Giusti AM, Marrer-Berger E, Boetsch C, et al. Src\/lck inhibitor dasatinib reversibly switches off cytokine release and T cell cytotoxicity following stimulation with T cell bispecific antibodies. J Immunother Cancer. 2021;9(7):e002582.","DOI":"10.1136\/jitc-2021-002582"},{"issue":"23","key":"3869_CR160","first-page":"4533","volume":"120","author":"Y Yang","year":"2012","unstructured":"Yang Y, Liu C, Peng W, Liz\u00e9e G, Overwijk WW, Liu Y, et al. Antitumor T-cell responses contribute to the effects of dasatinib on c-KIT mutant murine mastocytoma and are potentiated by anti-OX40. Blood J Am Soc Hematol. 2012;120(23):4533\u201343.","journal-title":"Blood J Am Soc Hematol"},{"issue":"1","key":"3869_CR161","doi-asserted-by":"publisher","first-page":"e24","DOI":"10.1016\/S2352-3026(22)00319-2","volume":"10","author":"E Jabbour","year":"2023","unstructured":"Jabbour E, Short NJ, Jain N, Huang X, Montalban-Bravo G, Banerjee P, et al. Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial. Lancet Haematol. 2023;10(1):e24\u201334.","journal-title":"Lancet Haematol"},{"key":"3869_CR162","doi-asserted-by":"publisher","first-page":"2662","DOI":"10.1182\/blood-2019-125966","volume":"134","author":"AH Wei","year":"2019","unstructured":"Wei AH, Fong CY, Montesinos P, Calbacho M, Gil JS, De Oteyza JP, et al. A phase 1 study of Flotetuzumab, a CD123 x CD3 DART\u00ae protein, combined with MGA012, an anti-PD-1 antibody, in patients with relapsed or refractory acute myeloid leukemia. Blood. 2019;134:2662.","journal-title":"Blood"}],"container-title":["Cancer Cell International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12935-025-03869-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12935-025-03869-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12935-025-03869-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T09:20:36Z","timestamp":1752139236000},"score":1,"resource":{"primary":{"URL":"https:\/\/cancerci.biomedcentral.com\/articles\/10.1186\/s12935-025-03869-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,7]]},"references-count":162,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3869"],"URL":"https:\/\/doi.org\/10.1186\/s12935-025-03869-w","relation":{},"ISSN":["1475-2867"],"issn-type":[{"value":"1475-2867","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,7]]},"assertion":[{"value":"23 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"254"}}